Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 16/20 | 0.48 |
| ▸ | PPARA | Q07869 | 11/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 5/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015484 | 0.90 | PPARD (0.59) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5015490 | 0.86 | PPARD (0.57) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5015463 | 0.86 | PPARD (0.47) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5016723 | 0.82 | PPARA (0.44) | PPARDPPARAPPARGMCL1 | |
| SCHEMBL5016817 | 0.81 | PPARD (0.48) | PPARDPPARAGRIN1GRIN2BPPARG | |
| SCHEMBL5017439 | 0.81 | PPARD (0.50) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5017515 | 0.80 | PPARD (0.49) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5017418 | 0.80 | TP53 (0.46) | PPARDPPARAPPARGMCL1 | |
| SCHEMBL6030017 | 0.80 | PPARD (0.47) | PPARDPPARAGRIN1GRIN2BPPARG | |
| SCHEMBL5015450 | 0.79 | PPARD (0.41) | PPARDPPARAPPARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644368-B1 | INDOLYL DERIVATIVES SUBSTITUTED WITH A THIAZOLE RING AND THEIR USE AS PPAR MODULATORS | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-7235572-B2 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20050004187-A1 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004187-A1 | Thiazolyl-indole derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | PPARD 1/4885PPARA 2/4885GRIN1 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.